System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Pascal Lenain is an expert in Hematology at Centre Henri Becquerel (France). Pascal Lenain has authored 131 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 1 of them ongoing. SLR score: 448 (community average: 125). How the SLR is computed.

LeadR Profile

Pascal Lenain Centre Henri Becquerel France
448 ScienceLeadR Reputation 448

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Public Health - Nutrition

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2009 - 2026
Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 131

Citations

Citations: 4 438 1st author: 0 Last author: 1 Unique author: 0

Main journals

Blood 40
Haematologica 8
Leukemia 8
J Clin Oncol 6
Leuk Res 6

Best Journals

J Clin Oncol 1
Lancet Oncol 1
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.
PMID 42069411 — interferon-alpha, therapeutics, suicide, attempted, suicide		Lancet Haematol20260
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study.
PMID 39540213 — hematology, dexamethasone, multiple myeloma, cytogenetics		Haematologica20251
Concordance between Tympanic and Enteral Temperature for Early Fever Detection in Hematologic Intensive Care Unit Patients: A Prospective Study.
PMID 40262543 — research design, hematology, ear, capsules, intensive care units, temperature, prospective studies		Acta Haematol20250
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
PMID 38084760 — transplantation, risk, drug-related side effects and adverse reactions, therapeutics, maintenance, disease-free survival, disease progression, multiple myeloma, dexamethasone, bortezomib, lenalidomide, progression-free survival		N Engl J Med Top journal2023230
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
PMID 36172814 — chromosome aberrations, hematology, risk, multiple myeloma, confidence intervals		Haematologica202314

Clinical Studies 14

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 6
Phase 2 5
N/A 2

By status:

Completed 7
Active not recruiting 2
Recruiting 2
Unknown 2

By type:

Interventional 13

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 0
multicentricup10 8

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Open label Study Comparing Iberdomide Daratumumab and Dexamethasone (IberDd) Versus Daratumumab Bortezomib and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997 — dexamethasone, bortezomib, multiple myeloma		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS